SynCardia To Bring TAH Ventricular Replacement Before FDA Panel In March
This article was originally published in The Gray Sheet
Executive Summary
SynCardia's CardioWest Total Artificial Heart (TAH) will be reviewed by FDA's Circulatory System Devices panel March 17 in Gaithersburg, Md
You may also be interested in...
SynCardia Plans U.S. Equivalency Trial Of Portable Total Artificial Heart
SynCardia's CardioWest Total Artificial Heart could be used in up to 500 U.S. cardiac transplant candidates annually, according to the firm
SynCardia Plans U.S. Equivalency Trial Of Portable Total Artificial Heart
SynCardia's CardioWest Total Artificial Heart could be used in up to 500 U.S. cardiac transplant candidates annually, according to the firm
St. Jude Optimistic About Symmetry Despite Slower-Than-Expected Adoption
Demand for St. Jude Medical's Symmetry anastomotic bypass graft system will continue to grow slowly for the foreseeable future, even though the device is associated with a better overall patency rate than traditional sutures, the company predicts